Recent Pfizer Press Releases

  • 5/1/07 4:15 pm EDT

    Lyrica is First Treatment Under FDA Review for Fibromyalgia, Which Affects More than Six Million Americans

    BOSTON--(BUSINESS WIRE)--Significantly more patients treated with Pfizer’s Lyrica reduced their pain by 50 percent or more compared with placebo, according to study results presented today at the American Academy of Neurology annual meeting. Clinically, this outcome would equate to a patient with severe pain reporting a reduction to mild to moderate pain. Fibromyalgia is one of the most common chronic, widespread pain conditions and ismore...
  • 4/30/07 4:24 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc reported today that the Federal Court of Appeal of Canada has reversed a lower court ruling that would have permitted generic manufacturer Novopharm to launch a competitor product to Celebrex. The appellate court issued an order prohibiting regulatory approval of Novopharm’s product in Canada until Celebrex’s compound patent expires in November 2014. “Today’s ruling is anmore...
  • 4/30/07 6:00 am EDT

    Academy for Educational Development and Johns Hopkins are Partnering with Pfizer to Evaluate the ConnectHIV Initiative

    NEW YORK--(BUSINESS WIRE)--The Pfizer Foundation today announced the names of 20 U.S. community-based AIDS service organizations (ASOs) chosen to participate in ConnectHIV, the Foundation’s latest initiative to support organizations working to stop the spread and impact of HIV/AIDS. ConnectHIV integrates lessons learned from the Southern HIV/AIDS Prevention Initiative, the Foundation’s recently completed 3-year prevention initiative tomore...
  • 4/27/07 12:32 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Vice Chairman David Shedlarz at the 32nd Annual Deutsche Bank Health Care Conference on Wednesday, May 2, at 11:15 a.m. Eastern Daylight Savings Time, and to listen to a webcast of participation by Vice Chairman David Shedlarz and other Pfizer executives in a discussion at the Morgan Stanley Global Healthcare Unpluggedmore...
  • 4/26/07 11:00 am EDT
    NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc today declared a 29-cent second-quarter, 2007, dividend on the company's common stock, payable June 5, 2007, to shareholders of record on May 11, 2007. Pfizer increased its quarterly dividend to 29 cents in the first quarter of 2007 as part of a series of actions the company is taking to enhance shareholder value. The second-quarter 2007 cash dividend will be the 274thmore...
  • 4/26/07 10:48 am EDT
    SOUTH BEND, Ind.--(BUSINESS WIRE)--In remarks at the annual shareholders meeting, Pfizer Chairman and Chief Executive Officer Jeffrey B. Kindler said, “We’re operating in an incredibly dynamic industry environment – one that, day in and day out, presents us with a whole range of promising opportunities. To succeed in this environment, we must fundamentally change the way we’ve done business in the past – and eventuallymore...
  • 4/26/07 7:00 am EDT

    Apixaban Currently in Phase III Trials for Prevention of Venous Thromboembolism and Prevention of Stroke Associated with Atrial Fibrillation

    Early-Stage Compounds Being Studied in Treatment of Metabolic Disorders

    PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc (NYSE: PFE) today announced a worldwide collaboration to develop and commercialize apixaban, an anticoagulant discovered by Bristol-Myers Squibb being studied for the prevention and treatment of a broad range of venous and arterial thrombotic conditions. In a separate agreement, the companies will also collaborate on the research, development andmore...
  • 4/24/07 5:43 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that the U.S. Food and Drug Administration’s (FDA) Antiviral Drugs Advisory Committee voted unanimously (12-0) to recommend the approval of maraviroc, a CCR5 antagonist, for use along with other antiretroviral agents for treatment-experienced patients infected with CCR5-tropic HIV-1. If approved, maraviroc would be the first member of a new class of oral HIV medicines in more than amore...
  • 4/20/07 6:43 am EDT
    • First-Quarter 2007 Revenues Grew 6 Percent to $12.5 Billion, Driven by Growth of New and In-Line Products, Foreign Exchange, and Other Factors
    • First-Quarter 2007 Adjusted Diluted EPS1 Increased 15 Percent to $.68, Reflecting Revenue Growth and Relatively Flat Operating Expenses; First-Quarter 2007 Reported Diluted EPS Decreased 14 Percent to $.48, Primarily Reflecting Restructuring Costs and 2006 One-Time Tax Benefit
    • Pfizer Updates Guidance for Full-Year 2007 Revenues and Full-Year 2007 Reported Diluted EPS and Adjusted Diluted EPS1 in Light of Earlier-than-Anticipated Loss of U.S. Exclusivity for Norvasc
    • Pfizer Provides Updated Guidance Range for Full-Year 2008 Revenues and Reconfirms Guidance for Full-Year 2008 Reported Diluted EPS and Adjusted Diluted EPS1
    • Ten Product Candidates in Cancer Portfolio to be Highlighted at June 2007 ASCO Meeting in 21 Oral Presentations and 49 Abstracts
    • Transformational Efforts Beginning to Show Benefits
    NEW YORK--(BUSINESS WIRE)--Pfizer: ($ billions, except per-share amounts) First Quarter   2007  2006  Revenues $12.474  $11.747  Reported Net Incomemore...
  • 4/19/07 3:41 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to listen to a Webcast of the Annual Meeting of Shareholders at 8:30 a.m. (Eastern Daylight Time) on Thursday, April 26. To access the Webcast, visit our Website at www.pfizer.com and click on the “Webcast of the Annual Meeting” link under the “Annual Meeting of Shareholders” section. Pre-registration for the Webcast will be available at that linkmore...